{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T05:24:21Z","timestamp":1794029061499,"version":"4.8.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,5,2]],"date-time":"2022-05-02T00:00:00Z","timestamp":1651449600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,2]],"date-time":"2022-05-02T00:00:00Z","timestamp":1651449600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>In older\/unfit newly diagnosed patients with <jats:italic>FLT3<\/jats:italic> mutated acute myeloid leukemia (AML), lower intensity chemotherapy (LIC) in combination with either a FLT3 inhibitor or with venetoclax results in poor overall survival (median 8 to 12.5 months). We performed a retrospective analysis of 87 newly diagnosed <jats:italic>FLT3<\/jats:italic> mutated AML patients treated on triplet (LIC\u2009+\u2009FLT3 inhibitor\u2009+\u2009Venetoclax, [<jats:italic>N<\/jats:italic>\u2009=\u200927]) and doublet (LIC\u2009+\u2009FLT3 inhibitor, [<jats:italic>N<\/jats:italic>\u2009=\u200960]) regimens at our institution. Data were collected from prospective clinical trials in 75% (<jats:italic>N<\/jats:italic>\u2009=\u200965) and 25% (<jats:italic>N<\/jats:italic>\u2009=\u200922) who received the same treatment regimens outside of a clinical trial. Triplet therapy was associated with significantly higher rates of complete remission (CR) (67% versus 32%, <jats:italic>P<\/jats:italic>\u2009=\u20090.002), CR\/CRi (93% versus 70%, <jats:italic>P<\/jats:italic>\u2009=\u20090.02), FLT3-PCR negativity (96% versus 54%, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.01), and flow-cytometry negativity (83% versus 38%, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.01) than doublets. At the end of the first cycle, the median time to ANC\u2009&gt;\u20090.5 (40 versus 21 days, <jats:italic>P<\/jats:italic>\u2009=\u20090.15) and platelet\u2009&gt;\u200950\u2009K (29 versus 25 days, <jats:italic>P<\/jats:italic>\u2009=\u20090.6) among responders was numerically longer with triplets, but 60-day mortality was similar (7% v 10%). With a median follow-up of 24 months (median 12 months for triplet arm, and 63 months for doublet arm), patients receiving a triplet regimen had a longer median overall survival (not reached versus 9.5 months, <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.01). LIC combined with FLT3 inhibitor and venetoclax (triplet) may be an effective frontline regimen for older\/unfit <jats:italic>FLT3<\/jats:italic> mutated AML that should be further validated prospectively.<\/jats:p>","DOI":"10.1038\/s41408-022-00670-0","type":"journal-article","created":{"date-parts":[[2022,5,2]],"date-time":"2022-05-02T09:02:58Z","timestamp":1651482178000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":64,"title":["Hypomethylating agent and venetoclax with FLT3 inhibitor \u201ctriplet\u201d therapy in older\/unfit patients with FLT3 mutated AML"],"prefix":"10.1038","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4498-4895","authenticated-orcid":false,"given":"Musa","family":"Yilmaz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1908-3307","authenticated-orcid":false,"given":"Hagop","family":"Kantarjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2983-2738","authenticated-orcid":false,"given":"Nicholas J.","family":"Short","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8433-3360","authenticated-orcid":false,"given":"Patrick","family":"Reville","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9347-2212","authenticated-orcid":false,"given":"Marina","family":"Konopleva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9892-9832","authenticated-orcid":false,"given":"Tapan","family":"Kadia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9003-0390","authenticated-orcid":false,"given":"Courtney","family":"DiNardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7679-6453","authenticated-orcid":false,"given":"Gautam","family":"Borthakur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1670-6513","authenticated-orcid":false,"given":"Naveen","family":"Pemmaraju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhishek","family":"Maiti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4465-6119","authenticated-orcid":false,"given":"Elias","family":"Jabbour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitin","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4339-8683","authenticated-orcid":false,"given":"Ghayas","family":"Issa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8027-9659","authenticated-orcid":false,"given":"Koichi","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9140-0610","authenticated-orcid":false,"given":"Koji","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maro","family":"Ohanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherry","family":"Pierce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9482-4806","authenticated-orcid":false,"given":"Guillin","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8980-3202","authenticated-orcid":false,"given":"Sanam","family":"Loghavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5081-2427","authenticated-orcid":false,"given":"Keyur","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sa A.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3631-2482","authenticated-orcid":false,"given":"Guillermo","family":"Garcia-Manero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1144-1958","authenticated-orcid":false,"given":"Michael","family":"Andreeff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7621-377X","authenticated-orcid":false,"given":"Farhad","family":"Ravandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7103-373X","authenticated-orcid":false,"given":"Naval","family":"Daver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,2]]},"reference":[{"key":"670_CR1","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1080\/1042819031000067503","volume":"44","author":"PD Kottaridis","year":"2003","unstructured":"Kottaridis PD, Gale RE, Linch DC. Prognostic implications of the presence of FLT3 mutations in patients with acute myeloid leukemia. Leuk Lymphoma. 2003;44:905\u201313.","journal-title":"Leuk Lymphoma"},{"key":"670_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00495-3","volume":"11","author":"N Daver","year":"2021","unstructured":"Daver N, Venugopal S, Ravandi F. FLT3 mutated acute myeloid leukemia: 2021 treatment algorithm. Blood Cancer J. 2021;11:104.","journal-title":"Blood Cancer J"},{"key":"670_CR3","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1056\/NEJMoa1614359","volume":"377","author":"RM Stone","year":"2017","unstructured":"Stone RM, Mandrekar SJ, Sanford BL, Laumann K, Geyer S, Bloomfield CD, et al. Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation. N. Engl J Med. 2017;377:454\u201364.","journal-title":"N. Engl J Med"},{"key":"670_CR4","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1002\/ajh.25198","volume":"93","author":"M Ohanian","year":"2018","unstructured":"Ohanian M, Garcia-Manero G, Levis M, Jabbour E, Daver N, Borthakur G, et al. Sorafenib combined with 5-azacytidine in older patients with untreated FLT3-ITD mutated acute myeloid leukemia. Am J Hematol. 2018;93:1136\u201341.","journal-title":"Am J Hematol"},{"key":"670_CR5","first-page":"1332","volume":"130","author":"MM Gallogly","year":"2017","unstructured":"Gallogly MM, Tomlinson BK, Bunner P, Caimi P, Craig M, de Lima M, et al. A Phase II Study of Midostaurin and 5-Azacitidine for elderly patients with acute myeloid leukemia. Blood 2017;130:1332. Supplement 1-","journal-title":"Blood"},{"key":"670_CR6","doi-asserted-by":"crossref","unstructured":"Swaminathan M, Kantarjian HM, Levis M, Guerra V, Borthakur G, Alvarado Y, et al. A phase I\/II study of the combination of quizartinib with azacitidine or low-dose cytarabine for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Haematologica. 2021;106:2121\u201330.","DOI":"10.3324\/haematol.2020.263392"},{"key":"670_CR7","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1182\/blood-2021-145379","volume":"138","author":"ES Wang","year":"2021","unstructured":"Wang ES, Montesinos P, Minden MD, Lee J-H, Heuser M, Naoe T, et al. Phase 3, Open-label, randomized study of Gilteritinib and Azacitidine Vs Azacitidine for newly diagnosed FLT3-mutated acute myeloid leukemia in patients ineligible for intensive induction chemotherapy. Blood 2021;138:700. Supplement 1-","journal-title":"Blood"},{"key":"670_CR8","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N. Engl J Med. 2020;383:617\u201329.","journal-title":"N. Engl J Med"},{"key":"670_CR9","doi-asserted-by":"publisher","unstructured":"Konopleva M, Thirman MJ, Pratz KW, Garcia JS, Recher C, Pullarkat V, et al. Impact of F LT3 mutation on outcomes after venetoclax and azacitidine for patients with treatment-naive acute myeloid leukemia. Clin Cancer Res. 2022. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-3405.","DOI":"10.1158\/1078-0432.CCR-21-3405"},{"key":"670_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-017-3383-5","volume":"17","author":"SK Tahir","year":"2017","unstructured":"Tahir SK, Smith ML, Hessler P, Rapp LR, Idler KB, Park CH, et al. Potential mechanisms of resistance to venetoclax and strategies to circumvent it. BMC Cancer. 2017;17:399.","journal-title":"BMC Cancer"},{"key":"670_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/srep27696","volume":"6","author":"KH Lin","year":"2016","unstructured":"Lin KH, Winter PS, Xie A, Roth C, Martz CA, Stein EM, et al. Targeting MCL-1\/BCL-XL forestalls the acquisition of resistance to ABT-199 in acute myeloid leukemia. Sci Rep. 2016;6:27696.","journal-title":"Sci Rep"},{"key":"670_CR12","doi-asserted-by":"crossref","unstructured":"Chyla B, Daver N, Doyle K, McKeegan E, Huang X, Ruvolo V, et al. Genetic biomarkers of sensitivity and resistance to venetoclax monotherapy in patients with relapsed acute myeloid leukemia. Am J Hematol. 2018;93:E202\u20135.","DOI":"10.1002\/ajh.25146"},{"key":"670_CR13","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1182\/blood.2019003988","volume":"135","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Tiong IS, Quaglieri A, MacRaild S, Loghavi S, Brown FC, et al. Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML. Blood 2020;135:791\u2013803.","journal-title":"Blood"},{"key":"670_CR14","doi-asserted-by":"publisher","first-page":"6815","DOI":"10.1158\/1078-0432.CCR-19-0832","volume":"25","author":"J Ma","year":"2019","unstructured":"Ma J, Zhao S, Qiao X, Knight T, Edwards H, Polin L, et al. Inhibition of Bcl-2 Synergistically enhances the antileukemic activity of midostaurin and gilteritinib in preclinical models of FLT3-mutated acute myeloid leukemia. Clin Cancer Res. 2019;25:6815\u201326.","journal-title":"Clin Cancer Res"},{"key":"670_CR15","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.3324\/haematol.2019.244020","volume":"106","author":"R Singh Mali","year":"2021","unstructured":"Singh Mali R, Zhang Q, DeFilippis RA, Cavazos A, Kuruvilla VM, Raman J, et al. Venetoclax combines synergistically with FLT3 inhibition to effectively target leukemic cells in FLT3-ITD+ acute myeloid leukemia models. Haematologica 2021;106:1034\u201346.","journal-title":"Haematologica"},{"key":"670_CR16","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/s13045-020-00973-4","volume":"13","author":"LT Brinton","year":"2020","unstructured":"Brinton LT, Zhang P, Williams K, Canfield D, Orwick S, Sher S, et al. Synergistic effect of BCL2 and FLT3 co-inhibition in acute myeloid leukemia. J Hematol Oncol. 2020;13:139.","journal-title":"J Hematol Oncol"},{"key":"670_CR17","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1038\/s41392-021-00578-4","volume":"6","author":"R Zhu","year":"2021","unstructured":"Zhu R, Li L, Nguyen B, Seo J, Wu M, Seale T, et al. FLT3 tyrosine kinase inhibitors synergize with BCL-2 inhibition to eliminate FLT3\/ITD acute leukemia cells through BIM activation. Signal Transduct Target Ther. 2021;6:186.","journal-title":"Signal Transduct Target Ther"},{"key":"670_CR18","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1182\/blood-2021-150743","volume":"138","author":"N Daver","year":"2021","unstructured":"Daver N, Perl AE, Maly J, Levis M, Ritchie E, Litzow MR, et al. Venetoclax in combination with gilteritinib demonstrates molecular clearance of FLT3 mutation in relapsed\/refractory FLT3-mutated acute myeloid leukemia. Blood 2021;138:691. Supplement 1-","journal-title":"Blood"},{"key":"670_CR19","first-page":"25","volume":"11","author":"A Maiti","year":"2021","unstructured":"Maiti A, DiNardo CD, Daver NG, Rausch CR, Ravandi F, Kadia TM, et al. Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia. Blood. Cancer J. 2021;11:25.","journal-title":"Cancer J"},{"key":"670_CR20","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1002\/cncr.30361","volume":"123","author":"F Ravandi","year":"2017","unstructured":"Ravandi F, Jorgensen J, Borthakur G, Jabbour E, Kadia T, Pierce S, et al. Persistence of minimal residual disease assessed by multiparameter flow cytometry is highly prognostic in younger patients with acute myeloid leukemia. Cancer 2017;123:426\u201335.","journal-title":"Cancer"},{"key":"670_CR21","doi-asserted-by":"publisher","first-page":"465","DOI":"10.3324\/haematol.2013.093765","volume":"99","author":"R Luthra","year":"2014","unstructured":"Luthra R, Patel KP, Reddy NG, Haghshenas V, Routbort MJ, Harmon MA, et al. Next-generation sequencing-based multigene mutational screening for acute myeloid leukemia using MiSeq: applicability for diagnostics and disease monitoring. Haematologica 2014;99:465\u201373.","journal-title":"Haematologica"},{"key":"670_CR22","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1158\/2643-3230.BCD-20-0143","volume":"2","author":"AS Alotaibi","year":"2021","unstructured":"Alotaibi AS, Yilmaz M, Kanagal-Shamanna R, Loghavi S, Kadia TM, DiNardo CD, et al. Patterns of resistance differ in patients with acute myeloid leukemia treated with Type I versus Type II FLT3 inhibitors. Blood Cancer Disco. 2021;2:125\u201334.","journal-title":"Blood Cancer Disco"},{"key":"670_CR23","doi-asserted-by":"publisher","first-page":"4642","DOI":"10.1200\/JCO.2003.04.036","volume":"21","author":"BD Cheson","year":"2003","unstructured":"Cheson BD, Bennett JM, Kopecky KJ, Buchner T, Willman CL, Estey EH, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2003;21:4642\u20139.","journal-title":"J Clin Oncol"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-022-00670-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-022-00670-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-022-00670-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,23]],"date-time":"2022-11-23T20:08:22Z","timestamp":1669234102000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-022-00670-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,2]]},"references-count":23,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022,5]]}},"alternative-id":["670"],"URL":"https:\/\/doi.org\/10.1038\/s41408-022-00670-0","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,2]]},"assertion":[{"value":"22 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"ND has received research funding from Daiichi Sankyo, Bristol-Myers Squibb, Pfizer, Karyopharm, Sevier, Genentech, Astellas, Sobi, Hanmi, Fate, Gilead, Forty-Seven, Trillium, KAHR, KITE, and ImmunoGen and has served in a consulting or advisory role for Daiichi Sankyo, Bristol-Myers Squibb, Pfizer, Syndax, Astellas, Immunogen, Glycostem, Novartis, Celgene, AbbVie, Arch oncology, KITE, Gilead, Servier, Trillium, Shattuck labs, and Agios. MY received research funding from Pfizer and Daiichi Sankyo. The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"77"}}